US investment group Bain Capital has agreed to buy Mitsubishi Tanabe Pharma for JPY 510 billion (around $3.4 billion), ...

With social media's history of hyped-up health trends, does a 'Mounjaro drink' drink deliver results - or is it just another internet myth? From 'sleepy girl cocktails' to 'oatzempic' drinks there ...

Following rumblings of a private equity bidding war late last year, Bain Capital has emer | Bain Capital is laying out 510 ...

Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief ...

Like most drugs, Mounjaro can cause side effects. Hair loss was not a reported side effect of Mounjaro, but it was reported with other GLP-1 agonists. Mounjaro can cause side effects, such as ...

Eli Lilly and Company LLY reported fourth-quarter 2024 adjusted earnings per share (“EPS”) of $5.32, which beat the Zacks ...

Recent medical evaluations have raised serious concerns about the safety of widely prescribed GLP-1 medications, such as Ozempic and Mounjaro, after emerging reports of vision complications.

Japan has one of the lowest obesity rates in ... could allow rival Eli Lilly to get ahead, when it launches its Mounjaro weight-loss drug.

With weight loss drugs such as Ozempic and Mounjaro seemingly able to melt the pounds away, you might well think you'll never need a 'diet plan' again. Alas, you'd be wrong. As a leading weight ...

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...

Higher volumes of drugs like Mounjaro, Zepbound, Verzenio, Jardiance and Taltz were partially offset by lower sales of Trulicity. Lilly’s new products also contributed to sales growth.